aflibercept

Key facts

Drug.MedlinePlus

a612004

Drug.Verifiedfields

changed

Drug.Watchedfields

changed

Drug.verifiedrevid

477243410

Drug.image

Aflibercept.png

Drug.tradename

Eylea, Zaltrap

Drug.DailyMedID

Aflibercept

Drug.pregnancy_AU

D

Drug.pregnancy_category

Not recommended

Drug.routes_of_administration

Intravenous, intravitreal injection

Drug.class

Antineovascularization agent

Drug.ATC_prefix

L01

Drug.ATC_suffix

XX44

Drug.biosimilars

aflibercept-abzv, aflibercept-ayyh, aflibercept-jbvf, aflibercept-mrbb, aflibercept-yszy, Ahzantive, Baiama, Enzeevu, Eydenzelt, Eyluxvi, Opuviz, Pavblu, Yesafili

Drug.legal_AU

S4

Drug.legal_CA

Rx-only

Drug.legal_UK

POM

Drug.legal_US

Rx-only

via Wikipedia infobox

• Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.Lancet (London, England) · 2024
• Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.Ophthalmology · 2012
• Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial.JAMA ophthalmology · 2021
• Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.Current opinion in ophthalmology · 2017
• Anatomic Outcomes with Faricimab vs Aflibercept in Head-to-Head Dosing Phase of the TENAYA/LUCERNE Trials in Neovascular Age-related Macular Degeneration.Ophthalmology · 2025

via PubMed